UOC
RCKT icon

UBS O'Connor’s Rocket Pharmaceuticals RCKT Stock Holding History

UBS O'Connor’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-20,000
Closed -$279K – 427
2020
Q1 		$279K Hold
20,000
– – 0.01% 289
2019
Q4 		$455K Buy
+20,000
New +$334K 0.01% 257
2018
Q3 		– Sell
-65,000
Closed -$1.28M – 323
2018
Q2 		$1.28M Buy
+65,000
New +$1.23M 0.03% 191

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

UBS O'Connor's RCKT Position: Q2 2020 in Review

UBS O'Connor sold out of Rocket Pharmaceuticals (RCKT) in Q2 2020, closing a stake of 20,000 shares — an estimated $279K sold.

UBS O'Connor first reported a position in RCKT in Q2 2018 and held it in 3 quarters. The position peaked at $1.28M in Q2 2018. 119 funds tracked by Wall St. Rank hold RCKT as of Q2 2020.

  • UBS O'Connor reported no remaining Rocket Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • UBS O'Connor sold 20,000 Rocket Pharmaceuticals shares in Q2 2020, an estimated $279K.
  • UBS O'Connor first reported a position in Rocket Pharmaceuticals in Q2 2018 and held it in 3 quarters.
  • UBS O'Connor's Rocket Pharmaceuticals position peaked at $1.28M in Q2 2018.
  • 119 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2020.

Based on UBS O'Connor's 13F filing for Q2 2020, filed 13 Aug 2020.